Literature DB >> 9560260

The CCR5 receptor acts as an alloantigen in CCR5Delta32 homozygous individuals: identification of chemokineand HIV-1-blocking human antibodies.

H J Ditzel1, M M Rosenkilde, P Garred, M Wang, K Koefoed, C Pedersen, D R Burton, T W Schwartz.   

Abstract

The chemokine receptor CCR5 is the major coreceptor for infection by macrophage-tropic R5 HIV-1. A 32-bp deletion in the gene coding for CCR5 (CCR5Delta32) occurs with a frequency of 10% in the Caucasian population and results in a receptor protein that is truncated and not expressed at the cell surface. CCR5Delta32 homozygous individuals are apparently normal but resistant to infection with R5 HIV-1. In two individuals homozygous for CCR5Delta32, who had been repeatedly exposed to CCR5-expressing blood cells through sexual activity, we have identified antibodies to CCR5 that bound specifically to the surface of CCR5-expressing cell lines. Serum from these individuals, in contrast to serum from CCR5(+/+) individuals, competed with radiolabeled RANTES for binding to the CCR5 receptor and inhibited infection of peripheral blood mononuclear cells with R5, but not X4, primary isolates of HIV-1. The identified human antibodies to CCR5 define an alloantigen that may cause allograft rejection in a mismatch situation even in individuals with no history of blood transfusions or i.v. drug abuse.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9560260      PMCID: PMC20245          DOI: 10.1073/pnas.95.9.5241

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  Erythrocyte receptors for (Plasmodium knowlesi) malaria: Duffy blood group determinants.

Authors:  L H Miller; S J Mason; J A Dvorak; M H McGinniss; I K Rothman
Journal:  Science       Date:  1975-08-15       Impact factor: 47.728

2.  Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection.

Authors:  R Liu; W A Paxton; S Choe; D Ceradini; S R Martin; R Horuk; M E MacDonald; H Stuhlmann; R A Koup; N R Landau
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

3.  CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1.

Authors:  G Alkhatib; C Combadiere; C C Broder; Y Feng; P E Kennedy; P M Murphy; E A Berger
Journal:  Science       Date:  1996-06-28       Impact factor: 47.728

Review 4.  Human antibodies from combinatorial libraries.

Authors:  D R Burton; C F Barbas
Journal:  Adv Immunol       Date:  1994       Impact factor: 3.543

5.  CC chemokine receptor 5 polymorphism in rheumatoid arthritis.

Authors:  P Garred; H O Madsen; J Petersen; H Marquart; T M Hansen; S Freiesleben Sørensen; B Volck; A Svejgaard; V Andersen
Journal:  J Rheumatol       Date:  1998-08       Impact factor: 4.666

6.  Chimeric NK1 (substance P)/NK3 (neurokinin B) receptors. Identification of domains determining the binding specificity of tachykinin agonists.

Authors:  U Gether; T E Johansen; T W Schwartz
Journal:  J Biol Chem       Date:  1993-04-15       Impact factor: 5.157

7.  A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor.

Authors:  R Horuk; C E Chitnis; W C Darbonne; T J Colby; A Rybicki; T J Hadley; L H Miller
Journal:  Science       Date:  1993-08-27       Impact factor: 47.728

8.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

Authors:  D R Burton; J Pyati; R Koduri; S J Sharp; G B Thornton; P W Parren; L S Sawyer; R M Hendry; N Dunlop; P L Nara
Journal:  Science       Date:  1994-11-11       Impact factor: 47.728

9.  Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells.

Authors:  F Cocchi; A L DeVico; A Garzino-Demo; S K Arya; R C Gallo; P Lusso
Journal:  Science       Date:  1995-12-15       Impact factor: 47.728

10.  Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure.

Authors:  W A Paxton; S R Martin; D Tse; T R O'Brien; J Skurnick; N L VanDevanter; N Padian; J F Braun; D P Kotler; S M Wolinsky; R A Koup
Journal:  Nat Med       Date:  1996-04       Impact factor: 53.440

View more
  10 in total

1.  Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression.

Authors:  Claudia Pastori; Barbara Weiser; Claudia Barassi; Caterina Uberti-Foppa; Silvia Ghezzi; Renato Longhi; Giliola Calori; Harold Burger; Kimdar Kemal; Guido Poli; Adriano Lazzarin; Lucia Lopalco
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

2.  Biased and constitutive signaling in the CC-chemokine receptor CCR5 by manipulating the interface between transmembrane helices 6 and 7.

Authors:  Anne Steen; Stefanie Thiele; Dong Guo; Lærke S Hansen; Thomas M Frimurer; Mette M Rosenkilde
Journal:  J Biol Chem       Date:  2013-03-14       Impact factor: 5.157

3.  Infection of macrophages and dendritic cells with primary R5-tropic human immunodeficiency virus type 1 inhibited by natural polyreactive anti-CCR5 antibodies purified from cervicovaginal secretions.

Authors:  Jobin Eslahpazir; Mohammad-Ali Jenabian; Hicham Bouhlal; Hakim Hocini; Cédric Carbonneil; Gérard Grésenguet; François-Xavier Mbopi Kéou; Jérôme LeGoff; Héla Saïdi; Mary Requena; Nadine Nasreddine; Jean de Dieu Longo; Srinivas V Kaveri; Laurent Bélec
Journal:  Clin Vaccine Immunol       Date:  2008-03-19

4.  Allo-immunization elicits CCR5 antibodies, SDF-1 chemokines, and CD8-suppressor factors that inhibit transmission of R5 and X4 HIV-1 in women.

Authors:  Y Wang; J Underwood; R Vaughan; A Harmer; C Doyle; T Lehner
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

Review 5.  Natural anti-CCR5 antibodies in HIV-infection and -exposure.

Authors:  Lucia Lopalco
Journal:  J Transl Med       Date:  2011-01-27       Impact factor: 5.531

6.  Biased small-molecule ligands for selective inhibition of HIV-1 cell entry via CCR5.

Authors:  Christian Berg; Katja Spiess; Hans R Lüttichau; Mette M Rosenkilde
Journal:  Pharmacol Res Perspect       Date:  2016-10-18

7.  The Abrogation of Phosphorylation Plays a Relevant Role in the CCR5 Signalosome Formation with Natural Antibodies to CCR5.

Authors:  Assunta Venuti; Claudia Pastori; Gabriel Siracusano; Rosamaria Pennisi; Agostino Riva; Massimo Tommasino; Maria Teresa Sciortino; Lucia Lopalco
Journal:  Viruses       Date:  2017-12-28       Impact factor: 5.048

8.  High-efficiency antibody discovery achieved with multiplexed microscopy.

Authors:  Shelley Mettler Izquierdo; Stephanie Varela; Minha Park; Ellen J Collarini; Daniel Lu; Shreya Pramanick; Joseph Rucker; Lucia Lopalco; Rob Etches; William Harriman
Journal:  Microscopy (Oxf)       Date:  2016-04-21       Impact factor: 1.571

Review 9.  Immunotherapy with Cell-Based Biological Drugs to Cure HIV-1 Infection.

Authors:  Gabriel Siracusano; Lucia Lopalco
Journal:  Cells       Date:  2021-12-28       Impact factor: 6.600

Review 10.  The Role of Natural Antibodies to CC Chemokine Receptor 5 in HIV Infection.

Authors:  Assunta Venuti; Claudia Pastori; Lucia Lopalco
Journal:  Front Immunol       Date:  2017-10-30       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.